{"id":"W2764070276","doi":"10.1200/jco.2017.35.15_suppl.e20502","title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Internal medicine; Brain metastasis; Nausea; Lung cancer; Refractory (planetary science); ALK inhibitor; Adverse effect; Vomiting; Gastroenterology; Oncology; Surgery; Cancer; Metastasis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009968414,0.0006375633,0.001050996,0.0002728337,0.0002188908,0.0006043813,0.0003675032,0.0006332678,0.003404563],"category_scores_gemma":[0.0009305181,0.0003002955,0.0006450382,0.0004111285,0.0002706868,0.0004410206,0.0002404956,0.001331148,0.0005750185],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006481833,"about_ca_system_score_gemma":0.000775619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009315268,"about_ca_topic_score_gemma":0.003964779,"domain_scores_codex":[0.9997258,0.0001542142,0.00002040501,0.00003851507,0.00002650308,0.00003462856],"domain_scores_gemma":[0.9997389,0.0000493176,0.00008893267,0.00001300016,0.00001675364,0.00009312735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8200763,0.007027925,0.01693152,0.002265315,0.002232022,0.0002762104,0.0001503121,0.001395314,0.01169364,0.0002658481,0.01492599,0.1227596],"study_design_scores_gemma":[0.8027229,0.1364393,0.04555171,0.0002100016,0.001640778,0.0006414526,0.00009095814,0.001446269,0.001724796,0.0003461707,0.009153522,0.00003227375],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758989,0.0153105,0.0002699411,0.001211778,0.0002274572,0.001371371,0.002180513,0.0001089142,0.003420676],"genre_scores_gemma":[0.9882251,0.004902271,0.0005678853,0.001077095,0.0001536865,0.000835975,0.002585414,0.0000131374,0.00163941],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003404563,"threshold_uncertainty_score":0.01138937,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06366795087877529,"score_gpt":0.4881444277727967,"score_spread":0.4244764768940214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}